Gsk (GLAXF) Cash from Discontinued Operations (2011 - 2026)

Gsk's Cash from Discontinued Operations history runs 9 years deep, the most recent figure standing at 1538271553.88 for Q1 2026.

• In Q1 2026, Cash from Discontinued Operations rose 6.67% year-over-year to 1538271553.88; the TTM figure through Mar 2026 stood at 10362832600.97 (down 26.28% YoY), while the FY2025 annual figure was 10206588510.3, up 21.83% from the prior year.
• Cash from Discontinued Operations was 1538271553.88 for Q1 2026 at Gsk, down from 3030118600.11 in the prior quarter.
• In the past five years, Cash from Discontinued Operations ranged from a high of 8412071055.38 in Q4 2024 to a low of 4691713.28 in Q4 2022.
• Historically, Cash from Discontinued Operations has averaged 2303996452.3 across 5 years, with a median of 1635531641.02 in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Discontinued Operations tumbled 99.14% in 2022, then jumped 84447.4% in 2023.
• A 5-year view of Cash from Discontinued Operations shows it stood at 4691713.28 in 2022, then surged by 84447.4% to 3966721425.69 in 2023, then soared by 112.07% to 8412071055.38 in 2024, then tumbled by 63.98% to 3030118600.11 in 2025, then slumped by 49.23% to 1538271553.88 in 2026.
• The last three Cash from Discontinued Operations figures came in at 1538271553.88 (Q1 2026), 3030118600.11 (Q4 2025), and 2998282692.11 (Q3 2025), per Business Quant data.